enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook

Company Overview - enGene Holdings (NASDAQ: ENGN) is a biotech company focused on developing gene therapies, particularly targeting specific forms of bladder cancer [1] - The company utilizes plasmid technology to advance its therapeutic approaches, aiming to demonstrate the efficacy of non-viral methods in treatment [1] Industry Insights - The biotech sector is increasingly exploring gene therapies as a viable treatment option for various cancers, indicating a growing trend towards innovative therapeutic solutions [1]